- Home
- NMCO vs VALN Comparison
NMCO vs VALN Comparison
Compare NMCO & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | VALN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | France |
| Employees | N/A | 674 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.1M | 494.0M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMCO | VALN |
|---|---|---|
| Price | $10.82 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 134.5K | 22.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $5.05 |
| 52 Week High | $11.00 | $12.25 |
Technical Indicators
Market Signals| Indicator | NMCO | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 35.32 |
| Support Level | $10.65 | $5.11 |
| Resistance Level | $10.96 | $5.49 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 97.37 | 31.52 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.